Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Crinetics Pharmaceuticals Inc (CRNX)

Crinetics Pharmaceuticals Inc (CRNX)
34.00 x 1 35.00 x 1
Post-market by (Cboe BZX)
34.62 -2.84 (-7.58%) 02/24/25 [NASDAQ]
34.00 x 1 35.00 x 1
Post-market 34.75 +0.13 (+0.38%) 17:15 ET
Quote Overview for Mon, Feb 24th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
34.09
Day High
37.68
Open 37.32
Previous Close 37.46 37.46
Volume 1,243,300 1,243,300
Avg Vol 769,225 769,225
Stochastic %K 32.57% 32.57%
Weighted Alpha -32.74 -32.74
5-Day Change -0.59 (-1.68%) -0.59 (-1.68%)
52-Week Range 34.07 - 62.53 34.07 - 62.53
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,473,965
  • Shares Outstanding, K 92,738
  • Annual Sales, $ 4,010 K
  • Annual Income, $ -214,530 K
  • EBIT $ -278 M
  • EBITDA $ -283 M
  • 60-Month Beta 0.56
  • Price/Sales 2,488.99
  • Price/Cash Flow N/A
  • Price/Book 3.60

Options Overview Details

View History
  • Implied Volatility 65.98% ( +8.01%)
  • Historical Volatility 69.90%
  • IV Percentile 91%
  • IV Rank 58.59%
  • IV High 88.58% on 03/15/24
  • IV Low 34.00% on 09/24/24
  • Put/Call Vol Ratio 0.30
  • Today's Volume 43
  • Volume Avg (30-Day) 22
  • Put/Call OI Ratio 0.80
  • Today's Open Interest 3,883
  • Open Int (30-Day) 3,996

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.92
  • Number of Estimates 9
  • High Estimate -0.80
  • Low Estimate -1.15
  • Prior Year -0.90
  • Growth Rate Est. (year over year) -2.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
34.07 +1.61%
on 02/12/25
Period Open: 38.79
41.07 -15.70%
on 01/31/25
-4.17 (-10.75%)
since 01/24/25
3-Month
34.07 +1.61%
on 02/12/25
Period Open: 56.06
60.34 -42.63%
on 12/11/24
-21.44 (-38.24%)
since 11/22/24
52-Week
34.07 +1.61%
on 02/12/25
Period Open: 36.85
62.53 -44.63%
on 11/14/24
-2.23 (-6.05%)
since 02/23/24

Most Recent Stories

More News
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

CRNX : 34.62 (-7.58%)
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences

CRNX : 34.62 (-7.58%)
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX : 34.62 (-7.58%)
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

CRNX : 34.62 (-7.58%)
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX : 34.62 (-7.58%)
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

CRNX : 34.62 (-7.58%)
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

CRNX : 34.62 (-7.58%)
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer

CRNX : 34.62 (-7.58%)
Crinetics Pharmaceuticals Grants Stock Options to New Employees Under 2021 Inducement Plan

Crinetics Pharmaceuticals granted stock options to 16 new employees under its 2021 Inducement Plan, totaling 146,400 shares.Quiver AI SummaryCrinetics Pharmaceuticals, Inc. announced the grant of non-qualified...

CRNX : 34.62 (-7.58%)
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRNX : 34.62 (-7.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly,...

See More

Key Turning Points

3rd Resistance Point 40.42
2nd Resistance Point 39.05
1st Resistance Point 36.83
Last Price 34.62
1st Support Level 33.25
2nd Support Level 31.88
3rd Support Level 29.66

See More

52-Week High 62.53
Fibonacci 61.8% 51.66
Fibonacci 50% 48.30
Fibonacci 38.2% 44.94
Last Price 34.62
52-Week Low 34.07

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements